Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
At the primary analysis, the trial did not meet its primary endpoint of overall survival (OS) The safety profile was consistent with previously reported studies of Onivyde (irinotecan liposomal
Humanigen, Inc. has been informed of preliminary topline results from the National Institute of Allergy and Infectious Diseases' ACTIV-5/BET-B trial evaluating lenzilumab plus remdesivir versus... | July 13, 2022
The U.S. Navy recently installed its first 3D printer aboard one of its vessels in a program designed to test the capabilities of the technology and i...
MacroGenics Announces Closure of CP-MGA271-06 Study Evaluating Enoblituzumab plus Checkpoint Inhibition in Head and Neck Cancer ROCKVILLE, MD, July 08, 2022 --... | July 8, 2022
Salt Lake City, Utah--(Newsfile Corp. - July 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced enrolling the first patient as a part of a Phase 2 study